RU2437888C2 - Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции - Google Patents
Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции Download PDFInfo
- Publication number
- RU2437888C2 RU2437888C2 RU2008145662/04A RU2008145662A RU2437888C2 RU 2437888 C2 RU2437888 C2 RU 2437888C2 RU 2008145662/04 A RU2008145662/04 A RU 2008145662/04A RU 2008145662 A RU2008145662 A RU 2008145662A RU 2437888 C2 RU2437888 C2 RU 2437888C2
- Authority
- RU
- Russia
- Prior art keywords
- indazol
- morpholinothieno
- pyrimidin
- pyrimidine
- methyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 49
- -1 thiopyranyl Chemical group 0.000 claims abstract 47
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 18
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 14
- 229910052799 carbon Inorganic materials 0.000 claims abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 150000002632 lipids Chemical class 0.000 claims abstract 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 10
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract 9
- 102000020233 phosphotransferase Human genes 0.000 claims abstract 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims abstract 8
- 230000000694 effects Effects 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 7
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 7
- 125000004452 carbocyclyl group Chemical group 0.000 claims abstract 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims abstract 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims abstract 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims abstract 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims abstract 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims abstract 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract 2
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims abstract 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 125000006413 ring segment Chemical group 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract 2
- 150000003852 triazoles Chemical class 0.000 claims abstract 2
- OXPJULAQXGHXMG-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(phenoxymethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1COC1=CC=CC=C1 OXPJULAQXGHXMG-UHFFFAOYSA-N 0.000 claims description 3
- SDAQMUGYAHYOTK-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(pyridin-2-ylmethoxymethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1COCC1=CC=CC=N1 SDAQMUGYAHYOTK-UHFFFAOYSA-N 0.000 claims description 3
- SNVYLDINYINJBQ-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(pyridin-3-ylmethoxymethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1COCC1=CC=CN=C1 SNVYLDINYINJBQ-UHFFFAOYSA-N 0.000 claims description 3
- SUUPOLANUWSKJH-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-n,n-dimethylpropanamide Chemical compound C=12SC(CCC(=O)N(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 SUUPOLANUWSKJH-UHFFFAOYSA-N 0.000 claims description 2
- RUYRUQRDGRFBMV-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(methylsulfonylmethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(CS(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 RUYRUQRDGRFBMV-UHFFFAOYSA-N 0.000 claims description 2
- USBBZDKANYQYJR-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(phenylmethoxymethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1COCC1=CC=CC=C1 USBBZDKANYQYJR-UHFFFAOYSA-N 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 102000038030 PI3Ks Human genes 0.000 claims 3
- 108091007960 PI3Ks Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- PCFRKLDFVDAEFU-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-6-phenylfuro[3,2-d]pyrimidine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1OC(C=1C=CC=CC=1)=C2 PCFRKLDFVDAEFU-UHFFFAOYSA-N 0.000 claims 2
- YKEDKDPZBFWVGS-UHFFFAOYSA-N 2-[2-(2-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=1N=C2NC(C)=NC2=CC=1C(N=C1SC(=CC1=1)C(C)(C)O)=NC=1N1CCOCC1 YKEDKDPZBFWVGS-UHFFFAOYSA-N 0.000 claims 2
- FFWWPZCGHGDPFH-UHFFFAOYSA-N 2-[4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-6-yl]propan-2-ol Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2SC(C(C)(O)C)=CC2=C1N1CCOCC1 FFWWPZCGHGDPFH-UHFFFAOYSA-N 0.000 claims 2
- UTIBOKQOUFWJBY-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(pyridin-4-ylmethoxymethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1COCC1=CC=NC=C1 UTIBOKQOUFWJBY-UHFFFAOYSA-N 0.000 claims 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 125000004411 C5-C6 heterocyclyl group Chemical group 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- JSRNAKDXAPQVRG-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]acetamide Chemical compound C=12SC(CNC(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JSRNAKDXAPQVRG-UHFFFAOYSA-N 0.000 claims 2
- ZVDDUFKZPHXCSI-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 ZVDDUFKZPHXCSI-UHFFFAOYSA-N 0.000 claims 2
- NSTMDEWDLPFQQT-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 NSTMDEWDLPFQQT-UHFFFAOYSA-N 0.000 claims 2
- RABOWVBQXMWRQH-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NCC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 RABOWVBQXMWRQH-UHFFFAOYSA-N 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- JMXRKVAGXKMIPZ-LLVKDONJSA-N (1r)-1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]ethanol Chemical compound C=12OC([C@H](O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JMXRKVAGXKMIPZ-LLVKDONJSA-N 0.000 claims 1
- VIOPFQOZMDFRIZ-LLVKDONJSA-N (1r)-1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]ethanol Chemical compound C=12SC([C@H](O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 VIOPFQOZMDFRIZ-LLVKDONJSA-N 0.000 claims 1
- JMXRKVAGXKMIPZ-NSHDSACASA-N (1s)-1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]ethanol Chemical compound C=12OC([C@@H](O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JMXRKVAGXKMIPZ-NSHDSACASA-N 0.000 claims 1
- VIOPFQOZMDFRIZ-NSHDSACASA-N (1s)-1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]ethanol Chemical compound C=12SC([C@@H](O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 VIOPFQOZMDFRIZ-NSHDSACASA-N 0.000 claims 1
- RKVSZDRDBKKPAP-MRXNPFEDSA-N (2r)-1-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]sulfonylpropan-2-ol Chemical compound C[C@@H](O)CS(=O)(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 RKVSZDRDBKKPAP-MRXNPFEDSA-N 0.000 claims 1
- RKVSZDRDBKKPAP-INIZCTEOSA-N (2s)-1-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]sulfonylpropan-2-ol Chemical compound C[C@H](O)CS(=O)(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 RKVSZDRDBKKPAP-INIZCTEOSA-N 0.000 claims 1
- DUCDTCHVXCKKRX-INIZCTEOSA-N (2s)-1-[3-[7-methyl-4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]phenyl]sulfonylpropan-2-ol Chemical compound C[C@H](O)CS(=O)(=O)C1=CC=CC(C2=C(C3=NC(=NC(=C3S2)N2CCOCC2)C=2C=C3C=CNC3=NC=2)C)=C1 DUCDTCHVXCKKRX-INIZCTEOSA-N 0.000 claims 1
- CUYITMLSLMYMHZ-ZDUSSCGKSA-N (2s)-1-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]propan-2-ol Chemical compound C=12SC(CNC[C@@H](O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 CUYITMLSLMYMHZ-ZDUSSCGKSA-N 0.000 claims 1
- BTXLWOORFZYYQO-HNNXBMFYSA-N (2s)-2-hydroxy-n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]propanamide Chemical compound C[C@H](O)C(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 BTXLWOORFZYYQO-HNNXBMFYSA-N 0.000 claims 1
- UYVMVHJNWHTYSN-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]methanone Chemical compound C1CC(O)CCN1C(=O)C1=CC2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2S1 UYVMVHJNWHTYSN-UHFFFAOYSA-N 0.000 claims 1
- WAEOVUWCYLULQY-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methanone Chemical compound C1CC(O)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 WAEOVUWCYLULQY-UHFFFAOYSA-N 0.000 claims 1
- VIURXCVRUARQCR-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-[3-[7-methyl-4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]phenyl]methanone Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2C(C)=C(C=3C=C(C=CC=3)C(=O)N3CCC(O)CC3)SC2=C1N1CCOCC1 VIURXCVRUARQCR-UHFFFAOYSA-N 0.000 claims 1
- HOWCYUAEDIVXNE-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[3-[4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-6-yl]phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C=2SC3=NC(=NC(=C3C=2)N2CCOCC2)C=2C=C3C=CNC3=NC=2)=C1 HOWCYUAEDIVXNE-UHFFFAOYSA-N 0.000 claims 1
- ZKFUDKPHKURGQZ-UHFFFAOYSA-N 1-(diethylamino)-2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=12SC(C(C)(O)CN(CC)CC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ZKFUDKPHKURGQZ-UHFFFAOYSA-N 0.000 claims 1
- JMXRKVAGXKMIPZ-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]ethanol Chemical compound C=12OC(C(O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JMXRKVAGXKMIPZ-UHFFFAOYSA-N 0.000 claims 1
- JYYZJYRXKDZPCT-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]-3-(4-methylsulfonylpiperazin-1-yl)propan-2-one Chemical compound C1CN(S(=O)(=O)C)CCN1CC(=O)CC1=CC2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2S1 JYYZJYRXKDZPCT-UHFFFAOYSA-N 0.000 claims 1
- NGGWNTYJNZWBMJ-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]ethanol Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(O)C)=CC2=C1N1CCOCC1 NGGWNTYJNZWBMJ-UHFFFAOYSA-N 0.000 claims 1
- ONWMYODREYYYMH-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-2-methylpropan-2-ol Chemical compound C=12SC(CC(C)(O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ONWMYODREYYYMH-UHFFFAOYSA-N 0.000 claims 1
- LSJWZUXCIJQWLS-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-n,n-dimethylmethanamine Chemical compound C=12SC(CN(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 LSJWZUXCIJQWLS-UHFFFAOYSA-N 0.000 claims 1
- NCWLVFNJIPBEOJ-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-n-methylmethanamine Chemical compound C=12SC(CNC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 NCWLVFNJIPBEOJ-UHFFFAOYSA-N 0.000 claims 1
- DSGDVGKDWAMYTM-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]cyclobutan-1-ol Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C1(O)CCC1 DSGDVGKDWAMYTM-UHFFFAOYSA-N 0.000 claims 1
- BKLQJXVOFOBSNX-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 BKLQJXVOFOBSNX-UHFFFAOYSA-N 0.000 claims 1
- HWFXCRFJUMYUFM-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpiperidin-4-ol Chemical compound C1CC(O)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 HWFXCRFJUMYUFM-UHFFFAOYSA-N 0.000 claims 1
- PNHATHRYVLOEIR-UHFFFAOYSA-N 1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpyrrolidin-3-ol Chemical compound C1C(O)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 PNHATHRYVLOEIR-UHFFFAOYSA-N 0.000 claims 1
- GROBNFFBQIRGSZ-UHFFFAOYSA-N 1-[4-(4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)-2,3-dihydroindol-1-yl]ethanone Chemical compound CC(=O)N1CCC2=C1C=CC=C2C(N=C1C=CSC1=1)=NC=1N1CCOCC1 GROBNFFBQIRGSZ-UHFFFAOYSA-N 0.000 claims 1
- CRCSKZIPKQHVOI-UHFFFAOYSA-N 1-[4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carbonyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2S1 CRCSKZIPKQHVOI-UHFFFAOYSA-N 0.000 claims 1
- KUUKIIAOCWZYSX-UHFFFAOYSA-N 1-[4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpiperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 KUUKIIAOCWZYSX-UHFFFAOYSA-N 0.000 claims 1
- LJKVWBKQZFRWPY-UHFFFAOYSA-N 1-[4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbonyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LJKVWBKQZFRWPY-UHFFFAOYSA-N 0.000 claims 1
- YCBDEZWXCLZIOY-UHFFFAOYSA-N 1-[4-hydroxy-4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1(O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 YCBDEZWXCLZIOY-UHFFFAOYSA-N 0.000 claims 1
- HMLURENDJQQGCM-UHFFFAOYSA-N 1-benzothiophene;pyridine Chemical compound C1=CC=NC=C1.C1=CC=C2SC=CC2=C1 HMLURENDJQQGCM-UHFFFAOYSA-N 0.000 claims 1
- HOCCUNWGIYBWLU-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)NCC(F)(F)F)=CC2=C1N1CCOCC1 HOCCUNWGIYBWLU-UHFFFAOYSA-N 0.000 claims 1
- JLVNYYWPIGRCTI-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-(2,2,2-trifluoroethyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCC(F)(F)F)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JLVNYYWPIGRCTI-UHFFFAOYSA-N 0.000 claims 1
- WRVFYDGHHSFFOC-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-(2-morpholin-4-ylethyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(=O)NCCN1CCOCC1 WRVFYDGHHSFFOC-UHFFFAOYSA-N 0.000 claims 1
- HCZPBIDLAMVEBA-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-(2-piperidin-1-ylethyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(=O)NCCN1CCCCC1 HCZPBIDLAMVEBA-UHFFFAOYSA-N 0.000 claims 1
- BHHHJNHPYSCFFH-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-(2-piperidin-1-ylethyl)thieno[3,2-d]pyrimidine-6-sulfonamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1S(=O)(=O)NCCN1CCCCC1 BHHHJNHPYSCFFH-UHFFFAOYSA-N 0.000 claims 1
- SMIDKUYBKUDRKB-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-phenylthieno[3,2-d]pyrimidin-6-amine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(NC=1C=CC=CC=1)=C2 SMIDKUYBKUDRKB-UHFFFAOYSA-N 0.000 claims 1
- ALOKKKPXBWDBSD-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(=O)NC1=CC=CC=C1 ALOKKKPXBWDBSD-UHFFFAOYSA-N 0.000 claims 1
- LGCKOOIOBWJBMG-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-propan-2-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)NC(C)C)=CC2=C1N1CCOCC1 LGCKOOIOBWJBMG-UHFFFAOYSA-N 0.000 claims 1
- DRBJFZFLAJGRGA-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-pyridin-2-ylthieno[3,2-d]pyrimidin-6-amine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(NC=1N=CC=CC=1)=C2 DRBJFZFLAJGRGA-UHFFFAOYSA-N 0.000 claims 1
- DLXYBNXLFJZKBH-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-yl-n-pyridin-3-ylthieno[3,2-d]pyrimidin-6-amine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(NC=1C=NC=CC=1)=C2 DLXYBNXLFJZKBH-UHFFFAOYSA-N 0.000 claims 1
- NIWKVJGJUJPBGK-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12OC(C(=O)N)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 NIWKVJGJUJPBGK-UHFFFAOYSA-N 0.000 claims 1
- UQEQBQDBQZQCJB-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)N)=CC2=C1N1CCOCC1 UQEQBQDBQZQCJB-UHFFFAOYSA-N 0.000 claims 1
- XNCSTYGCHDBACY-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)O)=CC2=C1N1CCOCC1 XNCSTYGCHDBACY-UHFFFAOYSA-N 0.000 claims 1
- FKOYCKMQWGADTH-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-amine Chemical compound C=12SC(N)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 FKOYCKMQWGADTH-UHFFFAOYSA-N 0.000 claims 1
- WWZAVDWPNSVWNN-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbonitrile Chemical compound C=12SC(C#N)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 WWZAVDWPNSVWNN-UHFFFAOYSA-N 0.000 claims 1
- YBGBXFWZMOYLQD-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)N)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 YBGBXFWZMOYLQD-UHFFFAOYSA-N 0.000 claims 1
- FDDMBVCMOPBZFJ-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-6-(3-methylsulfonylphenyl)-4-morpholin-4-ylfuro[3,2-d]pyrimidine Chemical compound CS(=O)(=O)C1=CC=CC(C=2OC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 FDDMBVCMOPBZFJ-UHFFFAOYSA-N 0.000 claims 1
- FHCJMLRUTSNNQI-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-6-(4-methoxypyridin-3-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidine Chemical compound COC1=CC=NC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2O1 FHCJMLRUTSNNQI-UHFFFAOYSA-N 0.000 claims 1
- KWWCMVDYTRYWPH-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n,n-dimethyl-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)N(C)C)=CC2=C1N1CCOCC1 KWWCMVDYTRYWPH-UHFFFAOYSA-N 0.000 claims 1
- BKDRTCOHEUFZFY-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n,n-dimethyl-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)N(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 BKDRTCOHEUFZFY-UHFFFAOYSA-N 0.000 claims 1
- FKIKJMKVWSALDP-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n,n-dimethyl-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-sulfonamide Chemical compound C=12SC(S(=O)(=O)N(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 FKIKJMKVWSALDP-UHFFFAOYSA-N 0.000 claims 1
- RDTCXYIQCWNFSK-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-(2-methoxyethyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCCOC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 RDTCXYIQCWNFSK-UHFFFAOYSA-N 0.000 claims 1
- INXCTOSJLMMDFQ-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-(2-methylpropyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCC(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 INXCTOSJLMMDFQ-UHFFFAOYSA-N 0.000 claims 1
- GUHFQJKAUMYZSE-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-(2-methylpropyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-sulfonamide Chemical compound C=12SC(S(=O)(=O)NCC(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 GUHFQJKAUMYZSE-UHFFFAOYSA-N 0.000 claims 1
- TYQMLTKFRJHHEU-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-(2-methylsulfonylethyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCCS(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 TYQMLTKFRJHHEU-UHFFFAOYSA-N 0.000 claims 1
- UAMBYKACPJDLSI-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-(3-methoxypropyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-sulfonamide Chemical compound C=12SC(S(=O)(=O)NCCCOC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 UAMBYKACPJDLSI-UHFFFAOYSA-N 0.000 claims 1
- ZNFNHTKIPYOTTI-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-methyl-4-morpholin-4-ylfuro[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12OC(C(=O)NC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ZNFNHTKIPYOTTI-UHFFFAOYSA-N 0.000 claims 1
- LWGYLFNPXUGWPI-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-methyl-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)NC)=CC2=C1N1CCOCC1 LWGYLFNPXUGWPI-UHFFFAOYSA-N 0.000 claims 1
- SSCACCUKDLQYBG-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 SSCACCUKDLQYBG-UHFFFAOYSA-N 0.000 claims 1
- CQGVZXXBDFUOHQ-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-sulfonamide Chemical compound C=12SC(S(=O)(=O)NC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 CQGVZXXBDFUOHQ-UHFFFAOYSA-N 0.000 claims 1
- RIGJAZFHROFODF-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-methylsulfonyl-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NS(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 RIGJAZFHROFODF-UHFFFAOYSA-N 0.000 claims 1
- RVAVFLAGEMAGCV-UHFFFAOYSA-N 2-(1h-indol-4-yl)-n-(2-methoxyethyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCCOC)=CC2=NC(C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 RVAVFLAGEMAGCV-UHFFFAOYSA-N 0.000 claims 1
- QDXYIFDFRQUYRJ-UHFFFAOYSA-N 2-(4-morpholin-4-yl-2-quinolin-3-ylthieno[2,3-d]pyrimidin-6-yl)propan-2-ol Chemical compound N1=C(C=2C=C3C=CC=CC3=NC=2)N=C2SC(C(C)(O)C)=CC2=C1N1CCOCC1 QDXYIFDFRQUYRJ-UHFFFAOYSA-N 0.000 claims 1
- SAGKGTRXWNMVQJ-UHFFFAOYSA-N 2-(4-morpholin-4-yl-2-quinolin-3-ylthieno[3,2-d]pyrimidin-6-yl)propan-2-ol Chemical compound C=12SC(C(C)(O)C)=CC2=NC(C=2C=C3C=CC=CC3=NC=2)=NC=1N1CCOCC1 SAGKGTRXWNMVQJ-UHFFFAOYSA-N 0.000 claims 1
- CZZWHEQOSGGGBN-UHFFFAOYSA-N 2-(dimethylamino)-n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound CN(C)CC(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 CZZWHEQOSGGGBN-UHFFFAOYSA-N 0.000 claims 1
- WKJOQYHMXRVQDK-UHFFFAOYSA-N 2-(dimethylamino)acetamide Chemical compound CN(C)CC(N)=O WKJOQYHMXRVQDK-UHFFFAOYSA-N 0.000 claims 1
- FTKOJEJLOFKOHM-UHFFFAOYSA-N 2-[1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpiperidin-4-yl]ethanol Chemical compound C1CC(CCO)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 FTKOJEJLOFKOHM-UHFFFAOYSA-N 0.000 claims 1
- IFSUIBXAHWRRLD-UHFFFAOYSA-N 2-[2-(1h-imidazo[4,5-b]pyridin-6-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=12SC(C(C)(O)C)=CC2=NC(C=2C=C3NC=NC3=NC=2)=NC=1N1CCOCC1 IFSUIBXAHWRRLD-UHFFFAOYSA-N 0.000 claims 1
- IPOHTGJEHGKOPX-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=12OC(C(C)(O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 IPOHTGJEHGKOPX-UHFFFAOYSA-N 0.000 claims 1
- UDTBHUGAUFWRRH-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]propan-2-ol Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(C)(O)C)=CC2=C1N1CCOCC1 UDTBHUGAUFWRRH-UHFFFAOYSA-N 0.000 claims 1
- VILXMSHZYWBRPI-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1,3-dimethoxypropan-2-ol Chemical compound C=12SC(C(O)(COC)COC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 VILXMSHZYWBRPI-UHFFFAOYSA-N 0.000 claims 1
- PERYMLMYBGAEAE-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1-methoxypropan-2-ol Chemical compound C=12SC(C(C)(O)COC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 PERYMLMYBGAEAE-UHFFFAOYSA-N 0.000 claims 1
- YWMSDMTVEOEPFB-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]ethanol Chemical compound C=12SC(CCO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 YWMSDMTVEOEPFB-UHFFFAOYSA-N 0.000 claims 1
- VARNVCFXTDKYGZ-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-amine Chemical compound C=12SC(C(C)(N)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 VARNVCFXTDKYGZ-UHFFFAOYSA-N 0.000 claims 1
- KYBJEPGFZBUXMW-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=12SC(C(C)(O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 KYBJEPGFZBUXMW-UHFFFAOYSA-N 0.000 claims 1
- TZKPJZZXKNAKRA-UHFFFAOYSA-N 2-[2-(1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=12SC(C(C)(O)C)=CC2=NC(C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 TZKPJZZXKNAKRA-UHFFFAOYSA-N 0.000 claims 1
- OVKKSLJAZQJVGU-UHFFFAOYSA-N 2-[2-(1h-indol-6-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=12SC(C(C)(O)C)=CC2=NC(C=2C=C3NC=CC3=CC=2)=NC=1N1CCOCC1 OVKKSLJAZQJVGU-UHFFFAOYSA-N 0.000 claims 1
- QHLSLQBAQLNCKK-UHFFFAOYSA-N 2-[2-(2-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=1N=C2NC(C)=NC2=CC=1C(N=C1C=C(SC1=1)C(C)(C)O)=NC=1N1CCOCC1 QHLSLQBAQLNCKK-UHFFFAOYSA-N 0.000 claims 1
- NSJBGAITKKJFCI-UHFFFAOYSA-N 2-[2-[[5-[7-methyl-4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]pyridin-2-yl]amino]ethoxy]ethanol Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2C(C)=C(C=3C=NC(NCCOCCO)=CC=3)SC2=C1N1CCOCC1 NSJBGAITKKJFCI-UHFFFAOYSA-N 0.000 claims 1
- WMAVDUZEBKWJIO-UHFFFAOYSA-N 2-[4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpiperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 WMAVDUZEBKWJIO-UHFFFAOYSA-N 0.000 claims 1
- VSTMOQHWDZKKBM-UHFFFAOYSA-N 2-[4-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]ethyl]piperazin-1-yl]-n,n-dimethylacetamide Chemical compound C1CN(CC(=O)N(C)C)CCN1CCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 VSTMOQHWDZKKBM-UHFFFAOYSA-N 0.000 claims 1
- ZHARFBOQSYPFLC-UHFFFAOYSA-N 2-[4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound C=12SC(C(C)(O)C)=CC2=NC(C=2C=C3C=CNC3=NC=2)=NC=1N1CCOCC1 ZHARFBOQSYPFLC-UHFFFAOYSA-N 0.000 claims 1
- PCYZABBVEPXYNB-UHFFFAOYSA-N 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]amino]ethanol Chemical compound C=12SC(NCCO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 PCYZABBVEPXYNB-UHFFFAOYSA-N 0.000 claims 1
- LTUYODIQJCESOZ-UHFFFAOYSA-N 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methoxy]-n,n-dimethylacetamide Chemical compound C=12SC(COCC(=O)N(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 LTUYODIQJCESOZ-UHFFFAOYSA-N 0.000 claims 1
- ZIOBGZDFMKCKGZ-UHFFFAOYSA-N 2-amino-2-methylpropanamide Chemical compound CC(C)(N)C(N)=O ZIOBGZDFMKCKGZ-UHFFFAOYSA-N 0.000 claims 1
- OJOJUIZMXGRZKQ-UHFFFAOYSA-N 2-amino-n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound NCC(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 OJOJUIZMXGRZKQ-UHFFFAOYSA-N 0.000 claims 1
- HSIDBIQATVJKLE-UHFFFAOYSA-N 2-amino-n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]acetamide Chemical compound C=12SC(CNC(=O)CN)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 HSIDBIQATVJKLE-UHFFFAOYSA-N 0.000 claims 1
- DRYMMXUBDRJPDS-UHFFFAOYSA-N 2-hydroxy-2-methylpropanamide Chemical compound CC(C)(O)C(N)=O DRYMMXUBDRJPDS-UHFFFAOYSA-N 0.000 claims 1
- JQYAUIWVBJZBFT-UHFFFAOYSA-N 2-hydroxy-n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]-2-methylpropanamide Chemical compound CC(C)(O)C(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 JQYAUIWVBJZBFT-UHFFFAOYSA-N 0.000 claims 1
- ABRHNDHZPLMMOG-UHFFFAOYSA-N 2-hydroxy-n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound OCC(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 ABRHNDHZPLMMOG-UHFFFAOYSA-N 0.000 claims 1
- ASETXJHJELKUBB-UHFFFAOYSA-N 2-hydroxy-n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n,2-dimethylpropanamide Chemical compound C=12SC(CN(C)C(=O)C(C)(C)O)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ASETXJHJELKUBB-UHFFFAOYSA-N 0.000 claims 1
- JRONZDANUVCFQC-UHFFFAOYSA-N 2-hydroxy-n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylacetamide Chemical compound C=12SC(CN(C)C(=O)CO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JRONZDANUVCFQC-UHFFFAOYSA-N 0.000 claims 1
- DMLJFVLZQZDUPU-UHFFFAOYSA-N 2-hydroxy-n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]acetamide Chemical compound C=12SC(CNC(=O)CO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 DMLJFVLZQZDUPU-UHFFFAOYSA-N 0.000 claims 1
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical compound NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 claims 1
- LJXFFVBNROKRCU-UHFFFAOYSA-N 3-(4-methylsulfonylpiperazin-1-yl)-2H-thieno[3,2-d]pyrimidine Chemical compound C1CN(S(=O)(=O)C)CCN1N1C=C2SC=CC2=NC1 LJXFFVBNROKRCU-UHFFFAOYSA-N 0.000 claims 1
- ZTPQKRRRSHFDTE-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 ZTPQKRRRSHFDTE-UHFFFAOYSA-N 0.000 claims 1
- GLSGPQCLQZUKEW-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound C1CN(C)CCN1C(=O)CCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 GLSGPQCLQZUKEW-UHFFFAOYSA-N 0.000 claims 1
- HPTFAYZZZKLPTE-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 HPTFAYZZZKLPTE-UHFFFAOYSA-N 0.000 claims 1
- LHDAJSMEICNCGD-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-n-methylpropanamide Chemical compound C=12SC(CCC(=O)NC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 LHDAJSMEICNCGD-UHFFFAOYSA-N 0.000 claims 1
- NUZFKPBYVJCPTM-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]aniline Chemical compound NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 NUZFKPBYVJCPTM-UHFFFAOYSA-N 0.000 claims 1
- ASDBHGFDAWIZBZ-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 ASDBHGFDAWIZBZ-UHFFFAOYSA-N 0.000 claims 1
- LQPMOWPBTLADQE-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]pentan-3-ol Chemical compound C=12SC(C(O)(CC)CC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 LQPMOWPBTLADQE-UHFFFAOYSA-N 0.000 claims 1
- SOMZVEMNUXOJBU-UHFFFAOYSA-N 3-[2-(1h-indazol-4-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C2=C(C3=NC(=NC(=C3S2)N2CCOCC2)C=2C=3C=NNC=3C=CC=2)C)=C1 SOMZVEMNUXOJBU-UHFFFAOYSA-N 0.000 claims 1
- OQUBNBKZUCUUCR-UHFFFAOYSA-N 3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1,1-dimethylurea Chemical compound C=12SC(CNC(=O)N(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 OQUBNBKZUCUUCR-UHFFFAOYSA-N 0.000 claims 1
- NBFZWXNPLNBPPB-UHFFFAOYSA-N 3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 NBFZWXNPLNBPPB-UHFFFAOYSA-N 0.000 claims 1
- HQDZWAWOKBSSBV-UHFFFAOYSA-N 3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 HQDZWAWOKBSSBV-UHFFFAOYSA-N 0.000 claims 1
- LCFDEBGLEMGHBK-UHFFFAOYSA-N 3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]-n,n-dimethylpropane-1-sulfonamide Chemical compound C=12SC(CNCCCS(=O)(=O)N(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 LCFDEBGLEMGHBK-UHFFFAOYSA-N 0.000 claims 1
- ROVNIUPCWOZOPP-UHFFFAOYSA-N 3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(NCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 ROVNIUPCWOZOPP-UHFFFAOYSA-N 0.000 claims 1
- OGHUYASKUOCABY-UHFFFAOYSA-N 3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]benzamide Chemical compound NC(=O)C1=CC=CC(NCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 OGHUYASKUOCABY-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- GZSPTLLIQXCXTM-UHFFFAOYSA-N 4-(4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)-1,3-dihydroindol-2-one Chemical compound N1C(=O)CC2=C1C=CC=C2C(N=C1C=CSC1=1)=NC=1N1CCOCC1 GZSPTLLIQXCXTM-UHFFFAOYSA-N 0.000 claims 1
- OTDJKLQPVUVGPE-UHFFFAOYSA-N 4-[2-(1h-imidazo[4,5-b]pyridin-6-yl)-7-methyl-6-(3-methylsulfonylphenyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound N1=C(C=2C=C3N=CNC3=NC=2)N=C2C(C)=C(C=3C=C(C=CC=3)S(C)(=O)=O)SC2=C1N1CCOCC1 OTDJKLQPVUVGPE-UHFFFAOYSA-N 0.000 claims 1
- DLCKOECVAPNZAU-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1-(1,3-thiazol-2-ylmethyl)piperidin-4-ol Chemical compound C1CC(O)(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CCN1CC1=NC=CS1 DLCKOECVAPNZAU-UHFFFAOYSA-N 0.000 claims 1
- RTOJMXWJUWQKMB-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1-(pyridin-2-ylmethyl)piperidin-4-ol Chemical compound C1CC(O)(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CCN1CC1=CC=CC=N1 RTOJMXWJUWQKMB-UHFFFAOYSA-N 0.000 claims 1
- QRJXGEXQFDTVMY-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1-methylpiperidin-4-ol Chemical compound C1CN(C)CCC1(O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 QRJXGEXQFDTVMY-UHFFFAOYSA-N 0.000 claims 1
- UKYNEFWWRRRHDS-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-1-methylsulfonylpiperidin-4-ol Chemical compound C1CN(S(=O)(=O)C)CCC1(O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 UKYNEFWWRRRHDS-UHFFFAOYSA-N 0.000 claims 1
- OELZEGOMYOORTR-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]thian-4-ol Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C1(O)CCSCC1 OELZEGOMYOORTR-UHFFFAOYSA-N 0.000 claims 1
- KOJNPSXCWFOWES-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(1,2,4-triazol-1-ylmethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1=NC=NN1CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 KOJNPSXCWFOWES-UHFFFAOYSA-N 0.000 claims 1
- WSBCPUUJZMZYHC-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(1,2-oxazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(C1=CON=C1)=C2 WSBCPUUJZMZYHC-UHFFFAOYSA-N 0.000 claims 1
- WRMXXCZQZKVCJU-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(C=1C=3C=CNC=3C=CC=1)=C2 WRMXXCZQZKVCJU-UHFFFAOYSA-N 0.000 claims 1
- JVGFOSCDMXXNRP-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(C1=CNN=C1)=C2 JVGFOSCDMXXNRP-UHFFFAOYSA-N 0.000 claims 1
- YQQHTYZMJGVSCJ-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 YQQHTYZMJGVSCJ-UHFFFAOYSA-N 0.000 claims 1
- KLIQKWLIFSOOQC-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(3-methoxypropylsulfonylmethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(CS(=O)(=O)CCCOC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 KLIQKWLIFSOOQC-UHFFFAOYSA-N 0.000 claims 1
- SYCRDWNPYYJLJB-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(3-methoxypyridin-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CN=CC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SYCRDWNPYYJLJB-UHFFFAOYSA-N 0.000 claims 1
- KHNNGVVMTDKSBL-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(3-methylsulfonylphenyl)thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound CS(=O)(=O)C1=CC=CC(C=2SC3=NC(=NC(=C3C=2)N2CCOCC2)C=2C=3C=NNC=3C=CC=2)=C1 KHNNGVVMTDKSBL-UHFFFAOYSA-N 0.000 claims 1
- IIYIOYDEXCGKMM-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(3-methylsulfonylphenyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound CS(=O)(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 IIYIOYDEXCGKMM-UHFFFAOYSA-N 0.000 claims 1
- RCTVICMXHIQSIZ-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(3-morpholin-4-ylprop-1-ynyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1CC#CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 RCTVICMXHIQSIZ-UHFFFAOYSA-N 0.000 claims 1
- YAGBWYDWEROTGK-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(3-pyrrolidin-1-ylprop-1-ynyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CCCN1CC#CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 YAGBWYDWEROTGK-UHFFFAOYSA-N 0.000 claims 1
- XDHDCRCCSVQZFV-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(4-methoxy-1-methylpiperidin-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C1(OC)CCN(C)CC1 XDHDCRCCSVQZFV-UHFFFAOYSA-N 0.000 claims 1
- DLSJNHFRWWVXIB-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(4-methoxypyridin-3-yl)-7-methylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CC=NC=C1C1=C(C)C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 DLSJNHFRWWVXIB-UHFFFAOYSA-N 0.000 claims 1
- CGMIWVPUJZBJEL-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(4-methoxypyridin-3-yl)thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CC=NC=C1C1=CC2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2S1 CGMIWVPUJZBJEL-UHFFFAOYSA-N 0.000 claims 1
- XPRXKQFDUTUXHX-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(4-methoxypyridin-3-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CC=NC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 XPRXKQFDUTUXHX-UHFFFAOYSA-N 0.000 claims 1
- GIMVQGMRVBRNLM-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(4-methylpiperazin-1-yl)sulfonylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 GIMVQGMRVBRNLM-UHFFFAOYSA-N 0.000 claims 1
- MONDJTSTNHPMQP-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(4-methylsulfonylphenyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MONDJTSTNHPMQP-UHFFFAOYSA-N 0.000 claims 1
- JFLITDAGHACDHY-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(4-methylsulfonylpiperazin-1-yl)sulfonylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(S(=O)(=O)C)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 JFLITDAGHACDHY-UHFFFAOYSA-N 0.000 claims 1
- UIOKQIDDKFTTPO-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(6-morpholin-4-ylpyridin-3-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=CC=C(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)C=N1 UIOKQIDDKFTTPO-UHFFFAOYSA-N 0.000 claims 1
- XVGVRYRNKLUWCP-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(methoxymethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(COC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 XVGVRYRNKLUWCP-UHFFFAOYSA-N 0.000 claims 1
- ZNDZHZSAEBKIFF-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(pyrazol-1-ylmethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1=CC=NN1CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 ZNDZHZSAEBKIFF-UHFFFAOYSA-N 0.000 claims 1
- WSHIYMFHSNIBIR-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-(pyridin-3-yloxymethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1COC1=CC=CN=C1 WSHIYMFHSNIBIR-UHFFFAOYSA-N 0.000 claims 1
- GFGLIVBBQQFKCY-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[(1-methylpiperidin-4-ylidene)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(C)CCC1=CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 GFGLIVBBQQFKCY-UHFFFAOYSA-N 0.000 claims 1
- IIVNSBQQAJSHHY-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[(2-methylimidazol-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound CC1=NC=CN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 IIVNSBQQAJSHHY-UHFFFAOYSA-N 0.000 claims 1
- DFLLILUQHRVESY-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[(5-methylsulfonyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1C2CN(S(=O)(=O)C)CC2CN1CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 DFLLILUQHRVESY-UHFFFAOYSA-N 0.000 claims 1
- ZHZNRUQJXPLVPO-ONEGZZNKSA-N 4-[2-(1h-indazol-4-yl)-6-[(e)-3-methoxyprop-1-enyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(/C=C/COC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ZHZNRUQJXPLVPO-ONEGZZNKSA-N 0.000 claims 1
- GDVXXRKFYMDOSS-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[1-(4-methylsulfonylpiperazin-1-yl)ethyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(C)N1CCN(S(C)(=O)=O)CC1 GDVXXRKFYMDOSS-UHFFFAOYSA-N 0.000 claims 1
- BPRVEWDTGCDGPT-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[2-(4-methylsulfonylpiperazin-1-yl)ethyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(S(=O)(=O)C)CCN1CCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 BPRVEWDTGCDGPT-UHFFFAOYSA-N 0.000 claims 1
- WZEMCHCPNXFMIV-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[2-(4-methylsulfonylpiperazin-1-yl)propan-2-yl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(C)(C)N1CCN(S(C)(=O)=O)CC1 WZEMCHCPNXFMIV-UHFFFAOYSA-N 0.000 claims 1
- MKJMAHCPYVPVMP-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[3-(4-methylpiperazin-1-yl)prop-1-ynyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(C)CCN1CC#CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MKJMAHCPYVPVMP-UHFFFAOYSA-N 0.000 claims 1
- CTWOVQPATIUQCL-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[3-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=CC=1CN1CCOCC1 CTWOVQPATIUQCL-UHFFFAOYSA-N 0.000 claims 1
- NGVJMWAVEDAYMS-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 NGVJMWAVEDAYMS-UHFFFAOYSA-N 0.000 claims 1
- PRWMGVLMVPVIMK-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-[3-[(4-methylsulfonylpiperazin-1-yl)methyl]phenyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 PRWMGVLMVPVIMK-UHFFFAOYSA-N 0.000 claims 1
- XPJGNKLLWVDSJB-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-methylsulfonylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(S(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 XPJGNKLLWVDSJB-UHFFFAOYSA-N 0.000 claims 1
- CSDWDEBIVURUIB-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-methylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 CSDWDEBIVURUIB-UHFFFAOYSA-N 0.000 claims 1
- LINPTOPIXQGUON-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-phenylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(C=1C=CC=CC=1)=C2 LINPTOPIXQGUON-UHFFFAOYSA-N 0.000 claims 1
- OPTQQZDVUHANCK-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-propylsulfonylthieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(S(=O)(=O)CCC)=CC2=C1N1CCOCC1 OPTQQZDVUHANCK-UHFFFAOYSA-N 0.000 claims 1
- KCQUVHOWDIPJMY-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-pyridin-3-ylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(C=1C=NC=CC=1)=C2 KCQUVHOWDIPJMY-UHFFFAOYSA-N 0.000 claims 1
- ISJSOSWFDBKPKH-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(C=1C=CN=CC=1)=C2 ISJSOSWFDBKPKH-UHFFFAOYSA-N 0.000 claims 1
- GZNWNSWUGCPFDU-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-6-pyrimidin-5-ylthieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC(C=1C=NC=NC=1)=C2 GZNWNSWUGCPFDU-UHFFFAOYSA-N 0.000 claims 1
- OMJFVWRGUNMBSO-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-7-methyl-6-(3-methylsulfonylphenyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2C(C)=C(C=3C=C(C=CC=3)S(C)(=O)=O)SC2=C1N1CCOCC1 OMJFVWRGUNMBSO-UHFFFAOYSA-N 0.000 claims 1
- GXJBABITGPOFCK-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=NC2=C1SC=C2 GXJBABITGPOFCK-UHFFFAOYSA-N 0.000 claims 1
- UXVQKIONVNQABP-UHFFFAOYSA-N 4-[2-(1h-indazol-6-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=C3NN=CC3=CC=2)=NC2=C1SC=C2 UXVQKIONVNQABP-UHFFFAOYSA-N 0.000 claims 1
- BRGOZBMFZJEZOD-UHFFFAOYSA-N 4-[2-(1h-indol-4-yl)-6-(2-methylsulfonylethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(CCS(=O)(=O)C)=CC2=NC(C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 BRGOZBMFZJEZOD-UHFFFAOYSA-N 0.000 claims 1
- BBAJVIVTBPZDOE-UHFFFAOYSA-N 4-[2-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=CNC=3C=CC=2)=NC2=C1SC=C2 BBAJVIVTBPZDOE-UHFFFAOYSA-N 0.000 claims 1
- UAYRLHUHRPLSPY-UHFFFAOYSA-N 4-[2-(1h-indol-5-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=C3C=CNC3=CC=2)=NC2=C1SC=C2 UAYRLHUHRPLSPY-UHFFFAOYSA-N 0.000 claims 1
- FACVJLFKESEKSB-UHFFFAOYSA-N 4-[2-(1h-indol-6-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=C3NC=CC3=CC=2)=NC2=C1SC=C2 FACVJLFKESEKSB-UHFFFAOYSA-N 0.000 claims 1
- KDHQHMPWDHZZED-UHFFFAOYSA-N 4-[2-(2-methylbenzimidazol-1-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound CC1=NC2=CC=CC=C2N1C(N=C1C=CSC1=1)=NC=1N1CCOCC1 KDHQHMPWDHZZED-UHFFFAOYSA-N 0.000 claims 1
- YFVQUSNMBHWKEY-UHFFFAOYSA-N 4-[3-(1h-indazol-4-yl)-6-[2-(4-methylsulfonylpiperazin-1-yl)propyl]-2h-thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(S(C)(=O)=O)CCN1C(C)CC(SC1=2)=CC1=NCN(C=1C=3C=NNC=3C=CC=1)C=2N1CCOCC1 YFVQUSNMBHWKEY-UHFFFAOYSA-N 0.000 claims 1
- DOYCWLGESOTTIQ-UHFFFAOYSA-N 4-[4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=C3C=CNC3=NC=2)=C1 DOYCWLGESOTTIQ-UHFFFAOYSA-N 0.000 claims 1
- ZNLQHFWSBQWQAA-UHFFFAOYSA-N 4-[6-(2-fluoropyridin-3-yl)-2-(1h-indazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=NC=CC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 ZNLQHFWSBQWQAA-UHFFFAOYSA-N 0.000 claims 1
- DPTOUGCBGLJTEU-UHFFFAOYSA-N 4-[6-(3,4-dimethoxyphenyl)-2-(1h-indazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 DPTOUGCBGLJTEU-UHFFFAOYSA-N 0.000 claims 1
- RAJPSTNLUWNLEK-UHFFFAOYSA-N 4-[6-(3-methylsulfonylphenyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound CS(=O)(=O)C1=CC=CC(C=2SC3=NC(=NC(=C3C=2)N2CCOCC2)C=2C=C3C=CNC3=NC=2)=C1 RAJPSTNLUWNLEK-UHFFFAOYSA-N 0.000 claims 1
- WVVVIUYWEYKSBO-UHFFFAOYSA-N 4-[6-(3-methylsulfonylphenyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound CS(=O)(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=C3C=CNC3=NC=2)=C1 WVVVIUYWEYKSBO-UHFFFAOYSA-N 0.000 claims 1
- WJPSFJLYFDPZQL-UHFFFAOYSA-N 4-[6-(6-fluoropyridin-3-yl)-2-(1h-indazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1=NC(F)=CC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 WJPSFJLYFDPZQL-UHFFFAOYSA-N 0.000 claims 1
- ZRVDTETZMKGCJC-UHFFFAOYSA-N 4-[6-(6-morpholin-4-ylpyridin-3-yl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=CC=C(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=C3C=CNC3=NC=2)C=N1 ZRVDTETZMKGCJC-UHFFFAOYSA-N 0.000 claims 1
- ZFXWZPQVEOYLAR-UHFFFAOYSA-N 4-[6-(imidazol-1-ylmethyl)-2-(1h-indazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1=CN=CN1CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 ZFXWZPQVEOYLAR-UHFFFAOYSA-N 0.000 claims 1
- YVXPBURFHIOTBL-UHFFFAOYSA-N 4-[6-chloro-2-(1h-indazol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(Cl)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 YVXPBURFHIOTBL-UHFFFAOYSA-N 0.000 claims 1
- XCYRTOCPTYYHAF-UHFFFAOYSA-N 4-[6-phenyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=C3C=CNC3=NC=2)=NC2=C1SC(C=1C=CC=CC=1)=C2 XCYRTOCPTYYHAF-UHFFFAOYSA-N 0.000 claims 1
- MREAPSSQNXBNMY-UHFFFAOYSA-N 4-[7-methyl-2-(2-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-6-(3-methylsulfonylphenyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1N=C2NC(C)=NC2=CC=1C(N=C1C(C)=C(SC1=1)C=2C=C(C=CC=2)S(C)(=O)=O)=NC=1N1CCOCC1 MREAPSSQNXBNMY-UHFFFAOYSA-N 0.000 claims 1
- CFPVHCXCHOSYFZ-UHFFFAOYSA-N 4-[7-methyl-6-(3-methylsulfonylphenyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2C(C)=C(C=3C=C(C=CC=3)S(C)(=O)=O)SC2=C1N1CCOCC1 CFPVHCXCHOSYFZ-UHFFFAOYSA-N 0.000 claims 1
- TZHQPMLOFDDRBR-UHFFFAOYSA-N 4-[7-methyl-6-phenyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2C(C)=C(C=3C=CC=CC=3)SC2=C1N1CCOCC1 TZHQPMLOFDDRBR-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- KPHKNRARMUEJAE-UHFFFAOYSA-N 5-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-n-methylpyridine-3-carboxamide Chemical compound CNC(=O)C1=CN=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 KPHKNRARMUEJAE-UHFFFAOYSA-N 0.000 claims 1
- ITOUAJPKDVQNOM-UHFFFAOYSA-N 5-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 ITOUAJPKDVQNOM-UHFFFAOYSA-N 0.000 claims 1
- DRBYPXKWMNCJND-UHFFFAOYSA-N 5-[7-methyl-4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]-n-(2-morpholin-4-ylethyl)pyridin-2-amine Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2C(C)=C(C=3C=NC(NCCN4CCOCC4)=CC=3)SC2=C1N1CCOCC1 DRBYPXKWMNCJND-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 239000004146 Propane-1,2-diol Substances 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- CGDNBRSICATCCM-UHFFFAOYSA-N [1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpiperidin-2-yl]methanol Chemical compound OCC1CCCCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 CGDNBRSICATCCM-UHFFFAOYSA-N 0.000 claims 1
- LOLXTZFSJNCISR-UHFFFAOYSA-N [1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpiperidin-3-yl]methanol Chemical compound C1C(CO)CCCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LOLXTZFSJNCISR-UHFFFAOYSA-N 0.000 claims 1
- XVOPDJREVPGIQS-UHFFFAOYSA-N [1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]sulfonylpiperidin-4-yl]methanol Chemical compound C1CC(CO)CCN1S(=O)(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 XVOPDJREVPGIQS-UHFFFAOYSA-N 0.000 claims 1
- ZCIUQVOMAJPLDW-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]-(4-methylsulfonylpiperazin-1-yl)methanone Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2O1 ZCIUQVOMAJPLDW-UHFFFAOYSA-N 0.000 claims 1
- OGOFABAHCDUSAR-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]methanol Chemical compound C=12OC(CO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 OGOFABAHCDUSAR-UHFFFAOYSA-N 0.000 claims 1
- MSHJILGQTIPLTK-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2S1 MSHJILGQTIPLTK-UHFFFAOYSA-N 0.000 claims 1
- NIQHQCXBSFZQDN-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]-(4-methylsulfonylpiperazin-1-yl)methanone Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)C1=CC2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2S1 NIQHQCXBSFZQDN-UHFFFAOYSA-N 0.000 claims 1
- NONWRRYWBPNJBW-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-(3-methylsulfonylpyrrolidin-1-yl)methanone Chemical compound C1C(S(=O)(=O)C)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 NONWRRYWBPNJBW-UHFFFAOYSA-N 0.000 claims 1
- DXLJYJMTRJPOMK-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 DXLJYJMTRJPOMK-UHFFFAOYSA-N 0.000 claims 1
- SMRKCXPZXJWDQL-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-(4-methylsulfanylphenyl)methanol Chemical compound C1=CC(SC)=CC=C1C(O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SMRKCXPZXJWDQL-UHFFFAOYSA-N 0.000 claims 1
- FYJKODWVFKPWDM-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-(4-methylsulfonylphenyl)methanol Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 FYJKODWVFKPWDM-UHFFFAOYSA-N 0.000 claims 1
- NAHOMCUIZWCREX-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-(4-methylsulfonylpiperazin-1-yl)methanone Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 NAHOMCUIZWCREX-UHFFFAOYSA-N 0.000 claims 1
- XQQQHUIJLNSUDW-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(=O)N(CC1)CCC1N1CCCC1 XQQQHUIJLNSUDW-UHFFFAOYSA-N 0.000 claims 1
- SKKLDCGZXGYZRO-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SKKLDCGZXGYZRO-UHFFFAOYSA-N 0.000 claims 1
- MVYHVEMJHZVMPK-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-morpholin-4-ylmethanone Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(=O)N1CCOCC1 MVYHVEMJHZVMPK-UHFFFAOYSA-N 0.000 claims 1
- COYPQVIZYKRPGC-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methanamine Chemical compound C=12SC(CN)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 COYPQVIZYKRPGC-UHFFFAOYSA-N 0.000 claims 1
- QLUFYDHSNDOTQX-UHFFFAOYSA-N [2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound C=12SC(CO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 QLUFYDHSNDOTQX-UHFFFAOYSA-N 0.000 claims 1
- PCENIFRDXVCQIG-UHFFFAOYSA-N [2-(1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound C=12SC(CO)=CC2=NC(C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 PCENIFRDXVCQIG-UHFFFAOYSA-N 0.000 claims 1
- JUZFJHWWBIFJDN-UHFFFAOYSA-N [3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 JUZFJHWWBIFJDN-UHFFFAOYSA-N 0.000 claims 1
- UIEXSKFFVPQKCK-UHFFFAOYSA-N [3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=CC=1C(=O)N1CCOCC1 UIEXSKFFVPQKCK-UHFFFAOYSA-N 0.000 claims 1
- NZMVTQYLBNMSMR-UHFFFAOYSA-N [3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]methanol Chemical compound OCC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 NZMVTQYLBNMSMR-UHFFFAOYSA-N 0.000 claims 1
- UEYJBPCMPKWSDB-UHFFFAOYSA-N [3-[7-methyl-4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C2=C(C3=NC(=NC(=C3S2)N2CCOCC2)C=2C=C3C=CNC3=NC=2)C)=C1 UEYJBPCMPKWSDB-UHFFFAOYSA-N 0.000 claims 1
- BXDHNDYGUMYFHE-UHFFFAOYSA-N [4-(2-hydroxyethyl)piperazin-1-yl]-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methanone Chemical compound C1CN(CCO)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 BXDHNDYGUMYFHE-UHFFFAOYSA-N 0.000 claims 1
- YEOIVKJHEWKRJW-UHFFFAOYSA-N [4-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 YEOIVKJHEWKRJW-UHFFFAOYSA-N 0.000 claims 1
- ZMVYOTLAHIRBEV-UHFFFAOYSA-N [5-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CN=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 ZMVYOTLAHIRBEV-UHFFFAOYSA-N 0.000 claims 1
- FEXXXTBNEHQOMC-UHFFFAOYSA-N [5-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]pyridin-3-yl]-morpholin-4-ylmethanone Chemical compound C=1N=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=CC=1C(=O)N1CCOCC1 FEXXXTBNEHQOMC-UHFFFAOYSA-N 0.000 claims 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- MNHMIRQVMGWCAV-UHFFFAOYSA-N formaldehyde;1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]piperazin-2-one Chemical compound O=C.O=C1CNCCN1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MNHMIRQVMGWCAV-UHFFFAOYSA-N 0.000 claims 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical compound CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- LVDDGWGYVMDQJK-UHFFFAOYSA-N methyl 3-amino-5-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]benzoate Chemical compound COC(=O)C1=CC(N)=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 LVDDGWGYVMDQJK-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- YRZBTENWLVQMCF-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)N(CCO)CCO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 YRZBTENWLVQMCF-UHFFFAOYSA-N 0.000 claims 1
- IWRDZFWSRFUGEI-UHFFFAOYSA-N n-(1-hydroxypropan-2-yl)-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NC(CO)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 IWRDZFWSRFUGEI-UHFFFAOYSA-N 0.000 claims 1
- MRACEBDYJBTUKS-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)NCCO)=CC2=C1N1CCOCC1 MRACEBDYJBTUKS-UHFFFAOYSA-N 0.000 claims 1
- XXMKMKMIJUMWFD-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCCO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 XXMKMKMIJUMWFD-UHFFFAOYSA-N 0.000 claims 1
- CGPUMAHJDNFYQW-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-sulfonamide Chemical compound C=12SC(S(=O)(=O)NCCO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 CGPUMAHJDNFYQW-UHFFFAOYSA-N 0.000 claims 1
- VBDSRKFHSYCRTB-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-[7-methyl-4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]benzenesulfonamide Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2C(C)=C(C=3C=C(C=CC=3)S(=O)(=O)NCCO)SC2=C1N1CCOCC1 VBDSRKFHSYCRTB-UHFFFAOYSA-N 0.000 claims 1
- QGPARBGAXRNGJC-UHFFFAOYSA-N n-(3-hydroxyphenyl)-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound OC1=CC=CC(NC(=O)C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 QGPARBGAXRNGJC-UHFFFAOYSA-N 0.000 claims 1
- QIZZOHYQGDTDSL-UHFFFAOYSA-N n-(cyclopropylmethoxy)-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(=O)NOCC1CC1 QIZZOHYQGDTDSL-UHFFFAOYSA-N 0.000 claims 1
- FABZXXJETVNBBX-UHFFFAOYSA-N n-(hydrazinecarbonyl)acetamide Chemical compound CC(=O)NC(=O)NN FABZXXJETVNBBX-UHFFFAOYSA-N 0.000 claims 1
- KIVOOCKLYREOKT-INIZCTEOSA-N n-[(2s)-2-hydroxypropyl]-3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]benzamide Chemical compound C[C@H](O)CNC(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 KIVOOCKLYREOKT-INIZCTEOSA-N 0.000 claims 1
- JRIGKCAVNHXYLK-UHFFFAOYSA-N n-[1-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbonyl]piperidin-4-yl]propanamide Chemical compound C1CC(NC(=O)CC)CCN1C(=O)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 JRIGKCAVNHXYLK-UHFFFAOYSA-N 0.000 claims 1
- ZTWBFYVBUNTWDG-UHFFFAOYSA-N n-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-2-methoxyacetamide Chemical compound C=12SC(NC(=O)COC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ZTWBFYVBUNTWDG-UHFFFAOYSA-N 0.000 claims 1
- GJKUTRCCCJZMCA-UHFFFAOYSA-N n-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-2-methylpropanamide Chemical compound C=12SC(NC(=O)C(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 GJKUTRCCCJZMCA-UHFFFAOYSA-N 0.000 claims 1
- LULULVBCWBKWGZ-UHFFFAOYSA-N n-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]-3,3-dimethylbutanamide Chemical compound C=12SC(NC(=O)CC(C)(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 LULULVBCWBKWGZ-UHFFFAOYSA-N 0.000 claims 1
- ZOPSPVOZYWKCJS-UHFFFAOYSA-N n-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]acetamide Chemical compound C=12SC(NC(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ZOPSPVOZYWKCJS-UHFFFAOYSA-N 0.000 claims 1
- QNLNTELZALDRKM-UHFFFAOYSA-N n-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 QNLNTELZALDRKM-UHFFFAOYSA-N 0.000 claims 1
- HKAOBTGSVCUELW-UHFFFAOYSA-N n-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propanamide Chemical compound C=12SC(NC(=O)CC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 HKAOBTGSVCUELW-UHFFFAOYSA-N 0.000 claims 1
- HJXHQGHFTGSJOK-UHFFFAOYSA-N n-[2-(dimethylamino)-2-oxoethyl]-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCC(=O)N(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 HJXHQGHFTGSJOK-UHFFFAOYSA-N 0.000 claims 1
- HLYXPODSMFLKJN-UHFFFAOYSA-N n-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 HLYXPODSMFLKJN-UHFFFAOYSA-N 0.000 claims 1
- JXRMAJJAKSGZET-UHFFFAOYSA-N n-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-yl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC(C)(C)C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 JXRMAJJAKSGZET-UHFFFAOYSA-N 0.000 claims 1
- BMOVDQUGLQDPOV-UHFFFAOYSA-N n-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC(C)(C)C1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 BMOVDQUGLQDPOV-UHFFFAOYSA-N 0.000 claims 1
- ZTRKBTZJFRRCAS-UHFFFAOYSA-N n-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-yl]acetamide Chemical compound C=12SC(C(C)(C)NC(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 ZTRKBTZJFRRCAS-UHFFFAOYSA-N 0.000 claims 1
- WTYHQVYOZDBNRV-UHFFFAOYSA-N n-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-yl]benzamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(C)(C)NC(=O)C1=CC=CC=C1 WTYHQVYOZDBNRV-UHFFFAOYSA-N 0.000 claims 1
- PUGFDZBXEJEBLD-UHFFFAOYSA-N n-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-yl]methanesulfonamide Chemical compound C=12SC(C(C)(NS(C)(=O)=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 PUGFDZBXEJEBLD-UHFFFAOYSA-N 0.000 claims 1
- KZXRGXVPZJQWHC-UHFFFAOYSA-N n-[2-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]propan-2-yl]pyridine-3-carboxamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1C(C)(C)NC(=O)C1=CC=CN=C1 KZXRGXVPZJQWHC-UHFFFAOYSA-N 0.000 claims 1
- DTMFFSITJJNBIH-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2OC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 DTMFFSITJJNBIH-UHFFFAOYSA-N 0.000 claims 1
- WNSMZRZEYUEEOQ-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2OC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 WNSMZRZEYUEEOQ-UHFFFAOYSA-N 0.000 claims 1
- NLVSATOETWMLEB-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2SC3=NC(=NC(=C3C=2)N2CCOCC2)C=2C=3C=NNC=3C=CC=2)=C1 NLVSATOETWMLEB-UHFFFAOYSA-N 0.000 claims 1
- IOFPTEMGEPNPAI-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 IOFPTEMGEPNPAI-UHFFFAOYSA-N 0.000 claims 1
- OEAFFLWWBWLOPU-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 OEAFFLWWBWLOPU-UHFFFAOYSA-N 0.000 claims 1
- ZVHZSNKNTKEEHU-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 ZVHZSNKNTKEEHU-UHFFFAOYSA-N 0.000 claims 1
- YYTJHTLEZIMJSV-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]propane-2-sulfonamide Chemical compound CC(C)S(=O)(=O)NC1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 YYTJHTLEZIMJSV-UHFFFAOYSA-N 0.000 claims 1
- OBHTYXZOTKNGQZ-UHFFFAOYSA-N n-[3-[2-(1h-indazol-4-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C2=C(C3=NC(=NC(=C3S2)N2CCOCC2)C=2C=3C=NNC=3C=CC=2)C)=C1 OBHTYXZOTKNGQZ-UHFFFAOYSA-N 0.000 claims 1
- TYKDMCBSMADXCT-UHFFFAOYSA-N n-[3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(NCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 TYKDMCBSMADXCT-UHFFFAOYSA-N 0.000 claims 1
- XHHQPDIIKLSWGG-UHFFFAOYSA-N n-[3-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(NCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 XHHQPDIIKLSWGG-UHFFFAOYSA-N 0.000 claims 1
- YEKCIGIILJVPAN-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidin-6-yl]methyl]-n-methylacetamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(CN(C)C(C)=O)=CC2=C1N1CCOCC1 YEKCIGIILJVPAN-UHFFFAOYSA-N 0.000 claims 1
- GWFIJUKVPLESNQ-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1-(3-methoxyphenyl)-n-methylmethanamine Chemical compound COC1=CC=CC(CN(C)CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 GWFIJUKVPLESNQ-UHFFFAOYSA-N 0.000 claims 1
- WQYLVVXCKBTNFS-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1h-pyrazol-5-amine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CNC1=CC=NN1 WQYLVVXCKBTNFS-UHFFFAOYSA-N 0.000 claims 1
- BRDAIOVATLRXRI-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 BRDAIOVATLRXRI-UHFFFAOYSA-N 0.000 claims 1
- QEJCCYYDBLSDCO-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 QEJCCYYDBLSDCO-UHFFFAOYSA-N 0.000 claims 1
- MOTJUNPNVGOULU-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2-(methanesulfonamido)acetamide Chemical compound C=12SC(CNC(=O)CNS(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 MOTJUNPNVGOULU-UHFFFAOYSA-N 0.000 claims 1
- HDDLCQGWIICNBM-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2-methoxy-n-(sulfonylmethyl)ethanamine Chemical compound C=12SC(CN(CCOC)C=S(=O)=O)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 HDDLCQGWIICNBM-UHFFFAOYSA-N 0.000 claims 1
- PAFOPKCPMIBOPH-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2-methoxy-n-methylacetamide Chemical compound C=12SC(CN(C)C(=O)COC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 PAFOPKCPMIBOPH-UHFFFAOYSA-N 0.000 claims 1
- FOTMTFMUZHDKCF-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2-methylsulfonylethanamine Chemical compound C=12SC(CNCCS(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 FOTMTFMUZHDKCF-UHFFFAOYSA-N 0.000 claims 1
- SLXPMTGNBXEIBN-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2-morpholin-4-yl-n-(sulfonylmethyl)ethanamine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CN(C=S(=O)=O)CCN1CCOCC1 SLXPMTGNBXEIBN-UHFFFAOYSA-N 0.000 claims 1
- BSLKSUJKWSCGQO-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 BSLKSUJKWSCGQO-UHFFFAOYSA-N 0.000 claims 1
- VHCHGAHSRJZYKY-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-3-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=CC(NCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 VHCHGAHSRJZYKY-UHFFFAOYSA-N 0.000 claims 1
- JSLZFIHIJSRJNR-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-3-methylsulfonylpropan-1-amine Chemical compound C=12SC(CNCCCS(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JSLZFIHIJSRJNR-UHFFFAOYSA-N 0.000 claims 1
- CXLVQGATPPPJKZ-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-4-methoxyaniline Chemical compound C1=CC(OC)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 CXLVQGATPPPJKZ-UHFFFAOYSA-N 0.000 claims 1
- AJOKQLNVCBVCPH-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 AJOKQLNVCBVCPH-UHFFFAOYSA-N 0.000 claims 1
- YQNJMWSXISDJTL-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-4-morpholin-4-ylaniline Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CNC(C=C1)=CC=C1N1CCOCC1 YQNJMWSXISDJTL-UHFFFAOYSA-N 0.000 claims 1
- DDNXFUFIIVAIJD-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-6-methoxypyridin-3-amine Chemical compound C1=NC(OC)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 DDNXFUFIIVAIJD-UHFFFAOYSA-N 0.000 claims 1
- CLJFVIIPYSNVBT-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-6-morpholin-4-ylpyridin-3-amine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CNC(C=N1)=CC=C1N1CCOCC1 CLJFVIIPYSNVBT-UHFFFAOYSA-N 0.000 claims 1
- FNOBKJZAYWXARK-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-(1-methylpyrrolidin-3-yl)methanesulfonamide Chemical compound C1N(C)CCC1N(S(C)(=O)=O)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 FNOBKJZAYWXARK-UHFFFAOYSA-N 0.000 claims 1
- XEFGTXIRCDZICI-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CN(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 XEFGTXIRCDZICI-UHFFFAOYSA-N 0.000 claims 1
- QFLFELVEHGJZRD-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methyl-3-morpholin-4-ylpropane-1-sulfonamide Chemical compound C1COCCN1CCCS(=O)(=O)N(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 QFLFELVEHGJZRD-UHFFFAOYSA-N 0.000 claims 1
- VGKRNNPCRRTVDX-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylacetamide Chemical compound C=12SC(CN(C)C(C)=O)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 VGKRNNPCRRTVDX-UHFFFAOYSA-N 0.000 claims 1
- VERXNRDKAMESJG-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylbenzamide Chemical compound C=1C=CC=CC=1C(=O)N(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 VERXNRDKAMESJG-UHFFFAOYSA-N 0.000 claims 1
- QWOQOLJMHPKEPG-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylmethanesulfonamide Chemical compound C=12SC(CN(C)S(C)(=O)=O)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 QWOQOLJMHPKEPG-UHFFFAOYSA-N 0.000 claims 1
- GDBWYDAADJKVFR-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]aniline Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CNC1=CC=CC=C1 GDBWYDAADJKVFR-UHFFFAOYSA-N 0.000 claims 1
- QNVPPKICOLKECD-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]cyclopropanesulfonamide Chemical compound C1CC1S(=O)(=O)NCC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 QNVPPKICOLKECD-UHFFFAOYSA-N 0.000 claims 1
- YGKCZWOYHXKHIM-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]methanesulfonamide Chemical compound C=12SC(CNS(=O)(=O)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 YGKCZWOYHXKHIM-UHFFFAOYSA-N 0.000 claims 1
- COLQZMFADBIQIF-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]morpholine-4-carboxamide Chemical compound C1COCCN1C(=O)NCC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 COLQZMFADBIQIF-UHFFFAOYSA-N 0.000 claims 1
- XFFDHPDURJDESH-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]pyridin-3-amine Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CNC1=CC=CN=C1 XFFDHPDURJDESH-UHFFFAOYSA-N 0.000 claims 1
- ZXRVOALNDVUFNX-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)NCC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 ZXRVOALNDVUFNX-UHFFFAOYSA-N 0.000 claims 1
- RLDSTQNQAQESLX-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylacetamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2C(C)=C(CN(C)C(C)=O)SC2=C1N1CCOCC1 RLDSTQNQAQESLX-UHFFFAOYSA-N 0.000 claims 1
- UKAWYOAEIQZFEL-UHFFFAOYSA-N n-[[2-(1h-indazol-4-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylmethanesulfonamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2C(C)=C(CN(C)S(C)(=O)=O)SC2=C1N1CCOCC1 UKAWYOAEIQZFEL-UHFFFAOYSA-N 0.000 claims 1
- JHZWLWGOVYIQKW-UHFFFAOYSA-N n-[[2-(1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methyl-3-morpholin-4-ylpropane-1-sulfonamide Chemical compound C1COCCN1CCCS(=O)(=O)N(C)CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=CC=1)=NC=2N1CCOCC1 JHZWLWGOVYIQKW-UHFFFAOYSA-N 0.000 claims 1
- BDYGRJQKNJPGMF-UHFFFAOYSA-N n-[[2-(1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylacetamide Chemical compound C=12SC(CN(C)C(C)=O)=CC2=NC(C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 BDYGRJQKNJPGMF-UHFFFAOYSA-N 0.000 claims 1
- MOTBSPARVVDJOU-UHFFFAOYSA-N n-[[2-(1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylmethanesulfonamide Chemical compound C=12SC(CN(C)S(C)(=O)=O)=CC2=NC(C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 MOTBSPARVVDJOU-UHFFFAOYSA-N 0.000 claims 1
- FBKQKZUNVMVVCX-UHFFFAOYSA-N n-[[2-(1h-indol-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylacetamide Chemical compound C=12SC(CN(C)C(C)=O)=CC2=NC(C=2C=C3C=CNC3=CC=2)=NC=1N1CCOCC1 FBKQKZUNVMVVCX-UHFFFAOYSA-N 0.000 claims 1
- CYFAGQCCUKPQGK-UHFFFAOYSA-N n-[[3-[4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-6-yl]phenyl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=CC=CC(C=2SC3=NC(=NC(=C3C=2)N2CCOCC2)C=2C=C3C=CNC3=NC=2)=C1 CYFAGQCCUKPQGK-UHFFFAOYSA-N 0.000 claims 1
- AABMTFMWGJXKIT-UHFFFAOYSA-N n-[[3-[7-methyl-4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]phenyl]methyl]methanesulfonamide Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2C(C)=C(C=3C=C(CNS(C)(=O)=O)C=CC=3)SC2=C1N1CCOCC1 AABMTFMWGJXKIT-UHFFFAOYSA-N 0.000 claims 1
- OHVNLFCAHUKGFE-UHFFFAOYSA-N n-cyclopropyl-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]acetamide Chemical compound C1CC1NC(=O)CNCC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 OHVNLFCAHUKGFE-UHFFFAOYSA-N 0.000 claims 1
- MTJYUWQSOPNLPR-UHFFFAOYSA-N n-ethyl-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2SC(C(=O)NCC)=CC2=C1N1CCOCC1 MTJYUWQSOPNLPR-UHFFFAOYSA-N 0.000 claims 1
- UOSGJGJNNZABLI-UHFFFAOYSA-N n-ethyl-2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C=12SC(C(=O)NCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 UOSGJGJNNZABLI-UHFFFAOYSA-N 0.000 claims 1
- JRSPQCFFSWGXFZ-UHFFFAOYSA-N n-ethyl-3-[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]benzamide Chemical compound CCNC(=O)C1=CC=CC(C=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)=C1 JRSPQCFFSWGXFZ-UHFFFAOYSA-N 0.000 claims 1
- LPRIICGUQQVMND-UHFFFAOYSA-N n-methyl-1-[4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl]methanamine Chemical compound C=12SC(CNC)=CC2=NC(C=2C=C3C=CNC3=NC=2)=NC=1N1CCOCC1 LPRIICGUQQVMND-UHFFFAOYSA-N 0.000 claims 1
- RIHBHCHGKDWCKN-UHFFFAOYSA-N n-methyl-n-[[4-morpholin-4-yl-2-(1h-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-6-yl]methyl]methanesulfonamide Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)N=C2SC(CN(C)S(C)(=O)=O)=CC2=C1N1CCOCC1 RIHBHCHGKDWCKN-UHFFFAOYSA-N 0.000 claims 1
- SVDVKEBISAOWJT-UHFFFAOYSA-N n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1 SVDVKEBISAOWJT-UHFFFAOYSA-N 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 claims 1
- UMHFSEWKWORSLP-UHFFFAOYSA-N thiophene 1,1-dioxide Chemical compound O=S1(=O)C=CC=C1 UMHFSEWKWORSLP-UHFFFAOYSA-N 0.000 claims 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 claims 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- MLYIJHRDTILUHI-UHFFFAOYSA-N C(COCC1)N1c1c2[s]cc(-c3cnc[s]3)c2nc(-c2cnc3[nH]ccc3c2)n1 Chemical compound C(COCC1)N1c1c2[s]cc(-c3cnc[s]3)c2nc(-c2cnc3[nH]ccc3c2)n1 MLYIJHRDTILUHI-UHFFFAOYSA-N 0.000 description 1
- JBVVAWHGLNEEGY-UHFFFAOYSA-N CS(N(CC1)CCN1C(CCc1cc(nc(-c2cccc3c2cn[nH]3)nc2N3CCOCC3)c2[s]1)=O)(=O)=O Chemical compound CS(N(CC1)CCN1C(CCc1cc(nc(-c2cccc3c2cn[nH]3)nc2N3CCOCC3)c2[s]1)=O)(=O)=O JBVVAWHGLNEEGY-UHFFFAOYSA-N 0.000 description 1
- DBPASBNPJMCLQI-UHFFFAOYSA-N NC(CCc1cc(nc(-c2cccc3c2cn[nH]3)nc2N3CCOCC3)c2[s]1)=O Chemical compound NC(CCc1cc(nc(-c2cccc3c2cn[nH]3)nc2N3CCOCC3)c2[s]1)=O DBPASBNPJMCLQI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79504706P | 2006-04-26 | 2006-04-26 | |
| US60/795,047 | 2006-04-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008145662A RU2008145662A (ru) | 2010-06-10 |
| RU2437888C2 true RU2437888C2 (ru) | 2011-12-27 |
Family
ID=38561741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008145662/04A RU2437888C2 (ru) | 2006-04-26 | 2007-04-24 | Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7846929B2 (enExample) |
| EP (1) | EP2046799B1 (enExample) |
| JP (1) | JP5291616B2 (enExample) |
| KR (1) | KR101402474B1 (enExample) |
| CN (1) | CN101511840A (enExample) |
| AR (1) | AR060632A1 (enExample) |
| AU (1) | AU2007243466B2 (enExample) |
| BR (1) | BRPI0710908A2 (enExample) |
| CA (1) | CA2650295C (enExample) |
| CL (1) | CL2007001166A1 (enExample) |
| IL (1) | IL194761A0 (enExample) |
| MX (1) | MX2008013583A (enExample) |
| NO (1) | NO20084927L (enExample) |
| RU (1) | RU2437888C2 (enExample) |
| TW (1) | TW200801012A (enExample) |
| WO (1) | WO2007127183A1 (enExample) |
| ZA (1) | ZA200810023B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2602739C2 (ru) * | 2012-05-07 | 2016-11-20 | Киссеи Фармасьютикал Ко., Лтд. | Производное пиразола и его применение в медицинских целях |
| RU2710549C2 (ru) * | 2015-03-30 | 2019-12-27 | Дайити Санкио Компани, Лимитед | Производное пиразола, пригодное в качестве ингибитора рi3к |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1679668B1 (en) * | 1996-09-04 | 2010-01-27 | Intertrust Technologies Corp. | Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management |
| TW200801012A (en) | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US8802670B2 (en) * | 2006-04-26 | 2014-08-12 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| ES2571028T3 (es) * | 2006-12-07 | 2016-05-23 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso |
| EP2114949A1 (en) * | 2006-12-07 | 2009-11-11 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| EP2129379B1 (en) * | 2007-02-20 | 2019-04-10 | Novartis AG | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
| US7893060B2 (en) * | 2007-06-12 | 2011-02-22 | F. Hoffmann-La Roche Ag | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| JP5658565B2 (ja) * | 2007-09-12 | 2015-01-28 | ジェネンテック, インコーポレイテッド | ホスホイノシチド3−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法 |
| CA2704711C (en) | 2007-09-24 | 2016-07-05 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| JP5348725B2 (ja) * | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| CA2703138A1 (en) * | 2007-10-26 | 2009-04-30 | F. Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
| GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| MX2010012437A (es) | 2008-05-14 | 2011-06-01 | Agriculture Victoria Serv Pty | Uso de angiogenina o agonistas de angiogenina para tratar enfermedades y trastornos. |
| WO2009146406A1 (en) * | 2008-05-30 | 2009-12-03 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
| PE20110403A1 (es) * | 2008-07-31 | 2011-07-04 | Genentech Inc | Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| CN102186845B (zh) * | 2008-10-17 | 2016-09-07 | 阿卡制药有限公司 | S1p受体调节剂以及它们的用途 |
| EP2344446A4 (en) | 2008-10-17 | 2012-04-04 | Akaal Pharma Pty Ltd | S1P RECEPTOR MODULATORS |
| KR20110098908A (ko) * | 2008-11-11 | 2011-09-02 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | PI3K/mTOR 키나제 억제제 |
| JP5689069B2 (ja) * | 2008-11-20 | 2015-03-25 | ジェネンテック, インコーポレイテッド | ピラゾロピリジンpi3k阻害剤化合物及び使用方法 |
| DK2385832T3 (en) | 2009-01-08 | 2015-09-21 | Curis Inc | Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel |
| MX363852B (es) | 2009-01-08 | 2019-04-05 | Merck Patent Gmbh | Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil} -6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion. |
| WO2010105008A2 (en) | 2009-03-12 | 2010-09-16 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| ES2665277T3 (es) * | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Análogos de purina y su uso como agentes inmunosupresores |
| US8785651B2 (en) | 2009-03-24 | 2014-07-22 | Sumitomo Chemical Company, Limited | Method for manufacturing a boronic acid ester compound |
| JP5766177B2 (ja) | 2009-03-27 | 2015-08-19 | ベトディーシー,インコーポレイテッド | ピリミジニル及び1,3,5−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用 |
| EP2451811A1 (en) * | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| AU2010254161A1 (en) * | 2009-05-27 | 2011-11-10 | F. Hoffmann-La Roche Ag | Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use |
| US20100331305A1 (en) * | 2009-06-24 | 2010-12-30 | Genentech, Inc. | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
| CA2987503C (en) | 2009-07-07 | 2019-02-26 | Mei Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011017520A1 (en) * | 2009-08-05 | 2011-02-10 | Wake Forest University Health Sciences | Compositions and methods for inducing apoptosis in prostate cancer cells |
| KR101721280B1 (ko) | 2009-08-17 | 2017-03-29 | 인텔리카인, 엘엘씨 | 헤테로사이클릭 화합물 및 이의 용도 |
| ES2534326T3 (es) | 2009-08-20 | 2015-04-21 | Karus Therapeutics Limited | Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa |
| CN102625708A (zh) * | 2009-09-09 | 2012-08-01 | 阿维拉制药公司 | Pi3激酶抑制剂及其用途 |
| WO2011030312A1 (en) * | 2009-09-10 | 2011-03-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
| NZ599090A (en) | 2009-09-28 | 2014-02-28 | Hoffmann La Roche | Benzoxepin pi3k inhibitor compounds and methods of use |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| EP3444242A3 (en) | 2009-11-05 | 2019-03-20 | Rhizen Pharmaceuticals S.A. | Novel benzopyran kinase modulators |
| RU2607635C2 (ru) * | 2009-11-12 | 2017-01-10 | Ф.Хоффманн-Ля Рош Аг | N-9-замещенные пуриновые соединения, композиции и способы применения |
| KR101447789B1 (ko) * | 2009-11-12 | 2014-10-06 | 에프. 호프만-라 로슈 아게 | N-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법 |
| US8633183B2 (en) * | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| CN102762565A (zh) | 2010-02-22 | 2012-10-31 | 弗·哈夫曼-拉罗切有限公司 | 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法 |
| UY33304A (es) * | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| WO2012007493A1 (en) | 2010-07-14 | 2012-01-19 | F. Hoffmann-La Roche Ag | Purine compounds selective for ρi3κ p110 delta, and methods of use |
| KR20140099556A (ko) | 2010-12-16 | 2014-08-12 | 에프. 호프만-라 로슈 아게 | 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법 |
| EP2667874A4 (en) * | 2011-01-27 | 2014-07-30 | Univ Princeton | MTOR KINASE HEMMER AS ANTIVIRUS AGENT |
| CN103476767B (zh) * | 2011-02-09 | 2015-06-10 | 弗·哈夫曼-拉罗切有限公司 | 作为pi3激酶抑制剂的杂环化合物 |
| CA2825966A1 (en) | 2011-03-21 | 2012-09-27 | F. Hoffmann-La Roche Ag | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
| EP2691384B1 (en) | 2011-03-28 | 2016-10-26 | MEI Pharma, Inc. | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
| ME02451B (me) | 2011-04-01 | 2016-09-20 | Curis Inc | Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| PT2705029T (pt) | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| KR101255939B1 (ko) * | 2011-05-31 | 2013-04-23 | 동화약품주식회사 | 4-(1h-인다졸-6-일아미노)-n-아이소프로필-2-(메틸티오)피리미딘-5-카르복스아미드 화합물 또는 이의 약학적으로 허용가능한 염을 포함하는 당뇨병 예방 또는 치료용 조성물 |
| CA2849331A1 (en) * | 2011-10-13 | 2013-04-18 | Genentech, Inc. | Treatment of pharmacological-induced hypochlorhydria |
| WO2013071264A1 (en) * | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| CN102643272B (zh) * | 2011-12-30 | 2015-03-11 | 沈阳药科大学 | 新的噻吩并[3,2-d]嘧啶类化合物 |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| FR2988722B1 (fr) | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
| WO2013152717A1 (zh) | 2012-04-10 | 2013-10-17 | 上海昀怡健康管理咨询有限公司 | 稠合嘧啶类化合物,其制备方法,中间体,组合物和应用 |
| WO2013158649A1 (en) | 2012-04-16 | 2013-10-24 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
| US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
| AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
| JP6301316B2 (ja) | 2012-05-23 | 2018-03-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法 |
| NZ702244A (en) | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| HRP20171610T1 (hr) | 2012-07-04 | 2018-03-23 | Rhizen Pharmaceuticals S.A. | Selektivni inhibitori pi3k delta |
| EP2890698B1 (en) * | 2012-08-30 | 2017-03-01 | F. Hoffmann-La Roche AG | Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use |
| WO2014068070A1 (en) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| CN104797573A (zh) | 2012-11-07 | 2015-07-22 | 卡鲁斯治疗有限公司 | 新的组蛋白脱乙酰基酶抑制剂及其在治疗中的用途 |
| MX2015014387A (es) * | 2013-04-12 | 2017-04-10 | Asana Biosciences Llc | Quinazolinas y azaquinazolinas como inhibidores duales de vias ras/raf/mek/erk y pi3k/akt/pten/mtor. |
| DK2994465T3 (en) | 2013-05-10 | 2018-10-08 | Karus Therapeutics Ltd | HISTONDEACETYLASE INHIBITORS UNKNOWN |
| DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| CN104513254B (zh) | 2013-09-30 | 2019-07-26 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| EP3057973B1 (en) | 2013-10-15 | 2019-09-04 | Case Western Reserve University | Compositions comprising a 15-pgdh inhibitor for the healing of wounds |
| KR101982912B1 (ko) | 2013-10-16 | 2019-09-10 | 상하이 잉리 파마슈티컬 컴퍼니 리미티드 | 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도 |
| BR112016017996A2 (pt) | 2014-02-06 | 2017-08-08 | Abbvie Inc | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| CN107921025A (zh) | 2015-03-08 | 2018-04-17 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| US20180057505A1 (en) * | 2015-03-20 | 2018-03-01 | Vertex Pharmaceuticals Incorporated | Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway |
| AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
| EP3283074A4 (en) * | 2015-04-14 | 2018-12-05 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| EP3314265B1 (en) | 2015-06-29 | 2019-07-24 | H. Hoffnabb-La Roche Ag | Methods of treatment with taselisib |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| CN109311868B (zh) | 2015-12-22 | 2022-04-01 | 尚医治疗有限责任公司 | 用于治疗癌症和炎性疾病的化合物 |
| CN107098846B (zh) * | 2016-02-26 | 2020-10-09 | 中国医学科学院药物研究所 | N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途 |
| US10947225B2 (en) | 2016-05-11 | 2021-03-16 | Emory University | Phosphotidylinositol 3-kinase inhibitors |
| CN120531733A (zh) | 2016-06-01 | 2025-08-26 | 礼蓝动物保健有限公司 | 用于治疗和预防动物的过敏性和/或炎症性疾病的取代吲唑 |
| WO2018057588A1 (en) * | 2016-09-21 | 2018-03-29 | Vertex Pharmaceuticals Incorporated | Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| CN110573154A (zh) | 2017-02-06 | 2019-12-13 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| KR20240097982A (ko) | 2017-05-23 | 2024-06-27 | 메이 파마, 아이엔씨. | 병용 요법 |
| IL271230B2 (en) * | 2017-06-21 | 2024-06-01 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| MX2020001727A (es) | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
| CN109796465B (zh) * | 2017-11-16 | 2020-07-14 | 华中科技大学同济医学院附属协和医院 | 靶向pet显像化合物、包含该化合物的显象剂及其制备方法和用途 |
| WO2019232403A1 (en) | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| WO2020055840A1 (en) | 2018-09-11 | 2020-03-19 | Curis Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| EP3863638B1 (en) * | 2018-10-12 | 2024-06-26 | Board of Regents of the University of Nebraska | Phosphodiesterase inhibitors |
| SG11202105345TA (en) | 2018-11-21 | 2021-06-29 | Univ Case Western Reserve | Compositions and methods of modulating short-chain dehydrogenase activity |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物 |
| JP7744350B2 (ja) | 2020-01-13 | 2025-09-25 | バージ アナリティクス,インコーポレイテッド | 置換ピラゾロ-ピリミジンおよびその使用 |
| EP4161519A4 (en) * | 2020-06-03 | 2024-07-17 | Yumanity Therapeutics, Inc. | PURINES AND METHODS OF USE |
| MX2023005436A (es) * | 2020-11-10 | 2023-07-25 | Foghorn Therapeutics Inc | Compuestos y usos de estos. |
| WO2022184152A1 (zh) * | 2021-03-03 | 2022-09-09 | 劲方医药科技(上海)有限公司 | 稠环取代的六元杂环化合物及其制法和用途 |
| WO2022266251A1 (en) * | 2021-06-16 | 2022-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions for treatment of psoriasis |
| CN115916775B (zh) * | 2021-06-22 | 2025-02-07 | 成都硕德药业有限公司 | Atr抑制剂及其用途 |
| CN118019744A (zh) * | 2021-09-30 | 2024-05-10 | 韩美药品株式会社 | PIKfyve激酶抑制剂 |
| CN115991716B (zh) * | 2021-10-19 | 2025-10-17 | 中国药科大学 | 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用 |
| US20250084078A1 (en) * | 2022-01-04 | 2025-03-13 | Genfleft Therapeutics (Shanghai) Inc. | Fused ring-substituted six-membered heterocyclic compound, and preparation method therefor and use thereof |
| CN114539293B (zh) * | 2022-02-24 | 2023-09-22 | 广东晨康生物科技有限公司 | 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用 |
| PE20250261A1 (es) | 2022-05-11 | 2025-01-29 | Foghorn Therapeutics Inc | Compuestos y usos de estos |
| CN117164590A (zh) * | 2022-05-25 | 2023-12-05 | 沈阳药科大学 | 稠合嘧啶类衍生物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU581868A3 (ru) * | 1973-10-02 | 1977-11-25 | Делаланд С.А. (Фирма) | Способ получени производных фуро32,3- /-пиримидина |
| US20030236271A1 (en) * | 2000-04-27 | 2003-12-25 | Masahiko Hayakawa | Fused heteroaryl derivatives |
| US20040053946A1 (en) * | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
| US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
| GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
| US4196207A (en) | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
| JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
| AU2002349912A1 (en) * | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| WO2003034997A2 (en) * | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| WO2004017950A2 (en) * | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| TW200801012A (en) | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| CN102625708A (zh) * | 2009-09-09 | 2012-08-01 | 阿维拉制药公司 | Pi3激酶抑制剂及其用途 |
-
2007
- 2007-04-24 TW TW096114440A patent/TW200801012A/zh unknown
- 2007-04-24 AR ARP070101760A patent/AR060632A1/es unknown
- 2007-04-24 RU RU2008145662/04A patent/RU2437888C2/ru not_active IP Right Cessation
- 2007-04-24 AU AU2007243466A patent/AU2007243466B2/en not_active Ceased
- 2007-04-24 MX MX2008013583A patent/MX2008013583A/es active IP Right Grant
- 2007-04-24 CN CNA2007800241241A patent/CN101511840A/zh active Pending
- 2007-04-24 CL CL2007001166A patent/CL2007001166A1/es unknown
- 2007-04-24 BR BRPI0710908-3A patent/BRPI0710908A2/pt not_active IP Right Cessation
- 2007-04-24 EP EP07776052.8A patent/EP2046799B1/en active Active
- 2007-04-24 WO PCT/US2007/009880 patent/WO2007127183A1/en not_active Ceased
- 2007-04-24 JP JP2009507753A patent/JP5291616B2/ja active Active
- 2007-04-24 CA CA2650295A patent/CA2650295C/en not_active Expired - Fee Related
- 2007-04-24 KR KR1020087028893A patent/KR101402474B1/ko not_active Expired - Fee Related
- 2007-04-24 US US11/789,427 patent/US7846929B2/en active Active
-
2008
- 2008-10-22 IL IL194761A patent/IL194761A0/en unknown
- 2008-11-25 ZA ZA200810023A patent/ZA200810023B/xx unknown
- 2008-11-25 NO NO20084927A patent/NO20084927L/no not_active Application Discontinuation
-
2010
- 2010-10-29 US US12/916,125 patent/US8450315B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU581868A3 (ru) * | 1973-10-02 | 1977-11-25 | Делаланд С.А. (Фирма) | Способ получени производных фуро32,3- /-пиримидина |
| US20030236271A1 (en) * | 2000-04-27 | 2003-12-25 | Masahiko Hayakawa | Fused heteroaryl derivatives |
| US20040053946A1 (en) * | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2602739C2 (ru) * | 2012-05-07 | 2016-11-20 | Киссеи Фармасьютикал Ко., Лтд. | Производное пиразола и его применение в медицинских целях |
| RU2710549C2 (ru) * | 2015-03-30 | 2019-12-27 | Дайити Санкио Компани, Лимитед | Производное пиразола, пригодное в качестве ингибитора рi3к |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2046799A1 (en) | 2009-04-15 |
| CA2650295A1 (en) | 2007-11-08 |
| ZA200810023B (en) | 2009-08-26 |
| EP2046799B1 (en) | 2017-07-19 |
| CN101511840A (zh) | 2009-08-19 |
| NO20084927L (no) | 2009-01-23 |
| CA2650295C (en) | 2015-12-29 |
| KR101402474B1 (ko) | 2014-06-19 |
| WO2007127183A1 (en) | 2007-11-08 |
| US8450315B2 (en) | 2013-05-28 |
| AU2007243466A1 (en) | 2007-11-08 |
| KR20090024682A (ko) | 2009-03-09 |
| AR060632A1 (es) | 2008-07-02 |
| US7846929B2 (en) | 2010-12-07 |
| US20080039459A1 (en) | 2008-02-14 |
| MX2008013583A (es) | 2008-10-31 |
| IL194761A0 (en) | 2009-08-03 |
| BRPI0710908A2 (pt) | 2012-06-26 |
| TW200801012A (en) | 2008-01-01 |
| CL2007001166A1 (es) | 2008-01-25 |
| JP5291616B2 (ja) | 2013-09-18 |
| JP2009535335A (ja) | 2009-10-01 |
| RU2008145662A (ru) | 2010-06-10 |
| US20110105464A1 (en) | 2011-05-05 |
| AU2007243466B2 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2437888C2 (ru) | Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции | |
| JP2009535335A5 (enExample) | ||
| TWI432431B (zh) | 調控c-fms及/或c-kit活性之化合物及其用途 | |
| RU2443706C2 (ru) | Фармацевтические соединения | |
| CA2729725C (en) | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | |
| JP5140600B2 (ja) | オーロラキナーゼのアザインドール阻害薬 | |
| KR101466412B1 (ko) | 피롤로피리미딘 화합물 및 그의 용도 | |
| KR101985984B1 (ko) | 키나아제 저해제로서의 벤조니트릴 유도체 | |
| KR102476459B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| AU2006216710B2 (en) | Imidazo (1, 2-A) pyridine compounds as VEGF-R2 inhibitors | |
| TWI343383B (en) | Pyrazole derivatives and uses thereof | |
| CA3122108A1 (en) | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors | |
| AU2009259867A1 (en) | Triazolopyridine JAK inhibitor compounds and methods | |
| AU2012299899A1 (en) | Bicyclic heteroaromatic compounds | |
| HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
| CA2670165A1 (en) | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | |
| CA2709883A1 (en) | Benzimidazoles and analogs as rho kinase inhibitors | |
| EA031409B1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| JP2011507854A5 (enExample) | ||
| JP2010512337A5 (enExample) | ||
| JP2020527174A5 (enExample) | ||
| TW202106684A (zh) | Raf激酶抑制劑 | |
| JP2020511549A (ja) | 有用な医薬用途を有する縮合トリアゾロ−ピリミジン化合物 | |
| JP2018509377A (ja) | 生体アミン輸送モジュレータとしてのヘテロ環式化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190425 |